CAR-T therapy transforms relapsed lymphoma into a race for treatment access
CAR-T therapy offers a lifeline for patients with relapsed blood cancers, but the real challenge is getting the treatment before time and logistics run out.
Tecartus 1 article
A specific combination of brexucabtagene autoleucel, CD19-directed CAR T-cell therapy and autologous T cells defines Tecartus as a therapeutic product. The intervention is further characterized by CD28 costimulatory domain, chimeric antigen receptor and mantle cell lymphoma, with B-cell acute lymphoblastic leukemia and ex vivo T-cell engineering placing it in its appropriate disease or delivery context. The tag remains specific to Tecartus, even when related therapies share autologous T cells.